Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of SLAMF7 recombinant protein in preparation of drugs for treating new coronal pneumonia

A new coronary pneumonia and drug technology, applied in the field of cell therapy, can solve the problems of patients with new coronary disease without approved drugs

Active Publication Date: 2020-11-03
THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, there are no FDA-approved drugs specifically for the treatment of COVID-19 patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of SLAMF7 recombinant protein in preparation of drugs for treating new coronal pneumonia
  • Application of SLAMF7 recombinant protein in preparation of drugs for treating new coronal pneumonia
  • Application of SLAMF7 recombinant protein in preparation of drugs for treating new coronal pneumonia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 The expression of SLAMF7 in patients with new coronavirus pneumonia and its clinical correlation

[0022] 5ml of peripheral blood was collected from 19 healthy volunteers and 37 patients with novel coronavirus pneumonia. Lymphocyte separation medium was used to separate PBMCs, and the expression of SLAMF7 in CD14+ monocyte-macrophages was detected by flow cytometry.

[0023] The result is as figure 1 As shown, compared with healthy people, the cell expression of SLAMF7 in patients with new coronary pneumonia was significantly upregulated in mononuclear macrophages ( figure 1 A); Compared with non-severe patients, the proportion of SLAMF7+CD14+ cells in severe patients is higher ( figure 1 B), indicating that the expression of SLAMF7 has a certain correlation with the course of the disease; SLAMF7+CD14+ cells are positively correlated with acute response protein CRP ( figure 1 C), indicating that the expression of SLAMF7 is also up-regulated with the exacerba...

Embodiment 2

[0024] Example 2 The effect of SLAMF7 recombinant protein on the production of inflammatory factors in PBMC stimulated by the N protein of the new coronavirus

[0025] Collect 10ml of peripheral blood from 10 healthy volunteers, and use lymphocyte separation medium to separate PBMC; use SLAMF7 recombinant protein and isotype control IgG to treat PBMC stimulated by the new coronavirus protein N protein, and detect inflammatory factors IL1A, IL1B, IL6 by qPCR after 24 hours mRNA expression levels. The stimulating concentration of the N protein is 1ug / ml; the concentration of the SLAMF7 recombinant protein is 1ug / ml; the isotype control is the isotype control antibody of the SLAMF7 recombinant protein, the concentration is 1ug / ml.

[0026] The result is as figure 2 As shown, the new coronavirus protein N protein promoted the production of inflammatory factors. Compared with the IgG group, the expression levels of IL1A, ILB, and IL6 decreased significantly after using the SLAMF7...

Embodiment 3

[0027] Example 3 The effect of SLAMF7 recombinant protein on the inflammatory factors produced by PBMC infected with the new coronavirus M pseudovirus

[0028] Collect 10ml of peripheral blood from 10 healthy volunteers, and use lymphocyte separation medium to separate PBMC; use SLAMF7 recombinant protein and isotype control IgG to treat PBMC infected with the new coronavirus M pseudovirus, and detect inflammatory factors IL1A, IL1B, IL6 by qPCR after 24 hours mRNA expression levels. The M pseudovirus infection MOI=5; the SLAMF7 recombinant protein and isotype control are as described in Example 1.

[0029] The result is as image 3 As shown, mock is the non-infected group, vector is the pseudovirus blank control group, and M is the M pseudovirus infection group; it can be seen from the results that the inflammatory factors IL1A and IL1B produced by the M pseudovirus infection were significantly inhibited after using the SLAMF7 recombinant protein , IL6 expression levels, in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of immunotherapy, and discloses a medicine for treating or adjunctively treating new coronapneumonia, the medicine can activate SLAMF7, and the expressionlevel of inflammatory factors generated by stimulating PBMC by new coronavirus protein can be obviously inhibited by activating the SLAMF7. According to the invention, SLAMF7 is used as a target for diagnosis / immunotherapy of new coronavirus pneumonia for the first time. New coronal pneumonia can be diagnosed by detecting the expression of SLAMF7 in mononuclear macrophages. Immunotherapy of new coronavirus pneumonia can be achieved by utilizing the SLAMF7 recombinant protein and the immunotherapy method thereof, and the method has the advantages of slowing down inflammatory factor storm, relieving inflammatory injury and the like, and is suitable for comprehensive treatment of new coronavirus pneumonia.

Description

technical field [0001] The present invention relates to the technical field of cell therapy, and more specifically, relates to the application of SLAMF7 recombinant protein in the preparation of drugs for treating COVID-19. Background technique [0002] The disease caused by SARS-CoV-2 is known as coronavirus disease 2019 (COVID-19 for short). Although most patients infected with SARS-CoV-2 had only mild symptoms, about 5% of patients developed severe lung damage or even multiple organ dysfunction. The study found that the levels of proinflammatory cytokines and chemokines TNF-α, IL-1β, IL-6, G-SCF, IP-10, MCP1, and MIP1α were significantly increased in COVID-19 patients. Similar to severe influenza, cytokine storm may play an important role in the immune pathogenic mechanism of COVID-19. Currently, there are no FDA-approved drugs specifically for treating patients with COVID-19. Cytokine blockers such as IL6 blockers can be used to inhibit the production of inflammatory ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68A61K39/395A61P31/14A61P11/00
CPCG01N33/6893A61K39/395A61P31/14A61P11/00G01N2800/12
Inventor 黄曦劳娟凤吴永坚
Owner THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com